Segui
Toon Van Gorp
Toon Van Gorp
Professor of Gynaecological Oncology @ University of Leuven
Email verificata su uzleuven.be
Titolo
Citata da
Citata da
Anno
HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
T Van Gorp, I Cadron, E Despierre, A Daemen, K Leunen, F Amant, ...
British journal of cancer 104 (5), 863-870, 2011
4282011
Endometriosis and the development of malignant tumours of the pelvis. A review of literature
T Van Gorp, F Amant, P Neven, I Vergote, P Moerman
Best practice & research Clinical obstetrics & gynaecology 18 (2), 349-371, 2004
4042004
Ovarian cancer
N Colombo, T Van Gorp, G Parma, F Amant, G Gatta, C Sessa, I Vergote
Critical reviews in oncology/hematology 60 (2), 159-179, 2006
3842006
Management of borderline ovarian neoplasms
I Cadron, K Leunen, T Van Gorp, F Amant, P Neven, I Vergote
Journal of clinical oncology 25 (20), 2928-2937, 2007
3032007
Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis
EMJ Meys, J Kaijser, R Kruitwagen, BFM Slangen, B Van Calster, ...
European Journal of Cancer 58, 17-29, 2016
2592016
Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients
IJG Rutten, DPJ van Dijk, RFPM Kruitwagen, RGH Beets‐Tan, ...
Journal of cachexia, sarcopenia and muscle 7 (4), 458-466, 2016
1932016
Lymph node metastasis in stages I and II ovarian cancer: a review
M Kleppe, T Wang, T Van Gorp, BFM Slangen, AJ Kruse, R Kruitwagen
Gynecologic oncology 123 (3), 610-614, 2011
1852011
Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer
IJG Rutten, J Ubachs, RFPM Kruitwagen, RGH Beets‐Tan, ...
Journal of cachexia, sarcopenia and muscle 8 (4), 630-638, 2017
1722017
Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant …
T Van Gorp, J Veldman, B Van Calster, I Cadron, K Leunen, F Amant, ...
European Journal of Cancer 48 (11), 1649-1656, 2012
1502012
A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
BJ Monk, C Parkinson, MC Lim, DM O'malley, A Oaknin, MK Wilson, ...
Journal of Clinical Oncology 40 (34), 3952, 2022
1472022
Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance—a study of the OVCAD consortium
E Obermayr, DC Castillo-Tong, D Pils, P Speiser, I Braicu, T Van Gorp, ...
Gynecologic oncology 128 (1), 15-21, 2013
1422013
Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer: a randomized controlled trial
MJ Rutten, HS Van Meurs, R Van De Vrie, CA Naaktgeboren, G Fons, ...
Journal of Clinical Oncology 35 (6), 613-621, 2017
1382017
Sarcopenia and ovarian cancer survival: a systematic review and meta‐analysis
J Ubachs, J Ziemons, IJG Minis‐Rutten, RFPM Kruitwagen, J Kleijnen, ...
Journal of cachexia, sarcopenia and muscle 10 (6), 1165-1174, 2019
1312019
The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma—analysis of patient data in the …
G Hofstetter, N Concin, I Braicu, R Chekerov, J Sehouli, I Cadron, ...
Gynecologic oncology 131 (1), 15-20, 2013
1282013
Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA–IV: analysis of the OVCAD data
S Polterauer, I Vergote, N Concin, I Braicu, R Chekerov, S Mahner, ...
International Journal of Gynecologic Cancer 22 (3), 2012
1282012
Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive
B Van Calster, I Vanden Bempt, M Drijkoningen, N Pochet, J Cheng, ...
Breast cancer research and treatment 113, 181-187, 2009
1262009
Timing of debulking surgery in advanced ovarian cancer
I Vergote, T Van Gorp, F Amant, K Leunen, P Neven, P Berteloot
International Journal of Gynecologic Cancer 18 (Suppl 1), 2008
1242008
Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods
EMJ Meys, LS Jeelof, NMJ Achten, BFM Slangen, S Lambrechts, ...
Ultrasound in Obstetrics & Gynecology 49 (6), 784-792, 2017
1122017
Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome
I Kalogiannidis, S Lambrechts, F Amant, P Neven, T Van Gorp, I Vergote
American journal of obstetrics and gynecology 196 (3), 248. e1-248. e8, 2007
1082007
The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery
IJG Rutten, J Ubachs, RFPM Kruitwagen, DPJ van Dijk, RGH Beets-Tan, ...
European Journal of Surgical Oncology (EJSO) 43 (4), 717-724, 2017
1072017
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20